Bristol, Sanofi seek permanent block of Plavix generic

01/18/2007 | Bloomberg

Bristol-Myers Squibb and Sanofi-Aventis plan to move in court to block resumed marketing of a generic version of their Plavix blood thinner, in a trial set to begin Monday. The suit over generics maker Apotex's challenge to the Plavix patent is seen as critical to Bristol-Myers because the drug is its best-seller. A judge ordered Apotex to quit marketing its version last August.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT